Spero Therapeutics (NASDAQ:SPRO) Downgraded by Wall Street Zen to "Hold"

Key Points

• Wall Street Zen downgraded Spero Therapeutics (NASDAQ:SPRO) from a "buy" to a "hold," while Weiss Ratings reiterated a "sell (d-)" and MarketBeat shows a consensus rating of "Reduce".
• Spero stock opened at $2.37 and was trading down about 4.0%, with a market capitalization of $133.53 million and a 52‑week range of $0.51 to $3.22.
• Insider Esther Rajavelu sold 87,917 shares at an average $2.36 (≈$207,484), reducing her position by 7.99%; insiders now own 5.50% and institutional investors own 25.60% after several recent small new stakes by firms like Invesco, Dimensional and Millennium.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Spero Therapeutics presently has a consensus rating of "Reduce".

Spero Therapeutics Trading Down 4.0%

Spero Therapeutics stock opened at $2.37 on Friday. The firm has a 50 day simple moving average of $2.36 and a 200 day simple moving average of $2.29. Spero Therapeutics has a 1-year low of $0.51 and a 1-year high of $3.22. The firm has a market capitalization of $133.53 million, a price-to-earnings ratio of -3.00 and a beta of 1.45.

Insider Buying and Selling at Spero Therapeutics

In other Spero Therapeutics news, insider Esther Rajavelu sold 87,917 shares of the firm's stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $2.36, for a total value of $207,484.12. Following the sale, the insider owned 1,012,091 shares of the company's stock, valued at $2,388,534.76. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in shares of Spero Therapeutics during the 2nd quarter valued at $43,000. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics during the 3rd quarter valued at $55,000. Millennium Management LLC purchased a new position in Spero Therapeutics in the 4th quarter worth $56,000. Assenagon Asset Management S.A. bought a new stake in Spero Therapeutics in the third quarter worth $70,000. Finally, Quadrature Capital Ltd bought a new stake in Spero Therapeutics in the fourth quarter worth $88,000. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.